Streptolydigin
From Wikipedia, the free encyclopedia
 |
|
|
Streptolydigin
|
|
| Systematic (IUPAC) name | |
| 2-[4-[6-(1,6-dimethylspiro[8,9-dioxabicyclo[3.3.1]non-3-ene-2,2'-oxirane]-7
-yl)-4-methylhepta-2,4-dienoyl]-5-hydroxy-1-(5-hydroxy-6-methyloxan-2-yl)-3 -oxo-2H-pyrrol-2-yl]-N-methylpropanamide |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C32H44N2O9 |
| Mol. mass | 600.708 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Streptolydigin is an antibiotic which works by blocking nucleic acid chain elongation by binding to the polymerase, thus stopping RNA polymerase activity inside a cell. Specifically, it inhibits the assembly of the RNA polymerase II transcription complex and DNA polymerase III transcription. It is active against a number of gram positive bacteria.
 |
This antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
